Navigation Links
Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
Date:9/11/2012

FORT WORTH, Texas, Sept. 11, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the initiation of a Phase III clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts. The study is designed to evaluate complete wound closure in subjects receiving HP802-247 plus compression therapy compared to those receiving vehicle control plus compression therapy over the 12-week treatment period.

Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.

"Following the favorable results achieved in our Phase IIb trial, we are very pleased to be initiating the Phase III study for this first-in-class cell-based therapy," commented Bert Slade, MD, FAAAAI, Chief Medical Officer at Healthpoint Biotherapeutics. "In addition to this multicenter North American study, our development strategy includes a second multicenter trial, which we plan to initiate next year at centers across Europe."

The North American study is a randomized, double-blind study involving subjects 18 years of age and older with venous leg ulcers of at least 6 weeks but not more than 24 months duration. The ulcers must be between 2 cm2 and 12 cm2 in area at presentation. Approximately 440 subjects will be enrolled across 45 investigational centers in the United States and Canada.

"As is evidenced by our ongoing $60 million investment in a state-of-the-art cell sciences research and manufacturing facility at our headquarters in Fort Worth, Healthpoint Biotherapeutics is committed to advancing the development of our lead pi
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
2. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
5. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
6. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
7. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
8. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
9. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
10. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
11. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... Echo Therapeutics, Inc. (NASDAQ: ... skin permeation, continuous glucose monitoring and associated technologies, ... has been appointed Chief Executive Officer effective December ... years of experience in the medical device, pharmaceutical ... as Vice President, Business Development, Otsuka Pharmaceuticals as well ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... Healthcare Products Association (CHPA), representing makers of over-the-counter ... U.S. Food and Drug Administration (FDA) efforts to ... right amount of medicine. Today, the FDA,s Nonprescription ... enhancing the labels of all OTC single-ingredient pediatric ...
... 2011 Eli Lilly and Company (NYSE: LLY ... scientific and medical officer of the American Diabetes Association, has ... from his current role in late-July. In his ... for Lilly Diabetes in advocacy and clinical science communities and ...
Cached Medicine Technology:OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 2OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 3David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly 2David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly 3
(Date:12/25/2014)... December 26, 2014 “Every three months the ... changes. A-line sweetheart evening dress will be one of the ... manager of Yunx.co.uk says. Today, the company releases 26 A-line ... up to 80% off. , “We are trying our ... style with our latest designs. Along with affordable prices, we ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 The short ... was created in honor of a true 9/11 hero, ... two film festivals including the 24 hours of Nuremberg International ... in Bangladesh. , Actress, screenwriter and director Luciana ... produce this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... But effect for women not same, as study cites obesity ... Vitamin K slows the development of insulin resistance in older ... resistance, a precursor to diabetes, occurs when the body cannot ... the blood. Overweight and obese people are prone to insulin ...
... 5 MetLife Mexico, Mexico City, Mexico, the largest ... a leading provider of such services to individual and ... Assist America, Inc., Princeton, N.J., the premier provider of ... 500,000 of its insureds with emergency travel assistance. ...
... The board of directors,for Hillenbrand, Inc. (NYSE: ... $0.185 per share on the company,s common stock, a ... per share. The dividend,is payable Dec. 31, 2008, to ... 17, 2008. Hillenbrand has paid quarterly dividends since its ...
... BlueShield today,announced that its employees committed more than $1 ... This amount is the,result of personal giving by ... Inc. , "In ... especially in need of help," said Mark Wagar, president ...
... heart problems, study says , , FRIDAY, Dec. 5 (HealthDay News) ... (IPF) are three times more likely than people without the ... attack, according to a British study. , "If you ... a threefold increased risk of acute coronary syndrome, which is ...
... 5 CANTEL MEDICAL CORP. (NYSE: ... diluted share, on a 7% increase in sales to $64,406,000 ... $0.02 of expenses related to the relocation of our Dutch ... income of $1,939,000, or $0.12 per diluted share, on sales ...
Cached Medicine News:Health News:Vitamin K Slows Insulin Resistance in Older Men 2Health News:MetLife Mexico Life Insurance Company Partners with Assist America for Global Emergency Medical Assistance Services 2Health News:Empire BlueCross BlueShield Associates Commit Over $1 Million to Community Organizations in 2008 2Health News:Lung Disease Tied to Increased Risk for Cardiac Events 2Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 2Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 3Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 4Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 5Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 6
... holes and additional electrode tip insulation, ... dissection with decreased risk of collateral ... ,Flexible design options allow the choice ... multiple tip designs. Optimize specific surgical ...
... Enhanced features including aspiration holes and ... laparoscopic procedures requiring precise dissection with ... increased suction demands. ,Flexible design ... and nonretractable electrodes and multiple tip ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: